Clinical Trial Update: Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial assessing safety and preliminary efficacy of anti-EBV autologous TCR-T cell therapy in relapsed/refractory EBV-positive lymphomas, including ext…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Extranodal Natural Killer T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Anti-EBV autologous TCR-T cell therapy

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) | EARLY_Phase 1 | Status: RECRUITING